Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review
The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.
How AAP's loss in Delhi elections could trigger a ripple effect in Punjab and beyond; Why it's a good news for Congress
Exit polls have been wrong before, but if these predictions prove accurate, AAP could be heading for a rough phase. A loss in ...